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Signiﬁcance of the prognostic
stratiﬁcation of extranodal
extension in colorectal cancer
We have to thank Huang and Yang for their very interesting
letter [1], in which they comment a recent meta-analysis of
our group of research [2], as well as a subsequent letter on the
same topic [3]. We recognize as important points those high-
lighted by Huang et al., particularly when they pointed out
that colon and rectal cancer are different in anatomic site, em-
bryological origin, function and also in metastatic patterns. At
the same time, we still consider of value the results of our
manuscript, in which we present the analysis on the prognostic
value of extranodal extension (ENE) of nodal metastasis con-
sidering colon and rectal cancer as one entity only. Notably,
we have also presented the hazard ratios of a signiﬁcant
number of studies and, in the subsequent letter, we have indi-
cated that the location has not been recognized as a probable
moderator of our ﬁndings (P = 0.229). The approach to con-
sider colon and rectal cancer together was further justiﬁed by
the fact that the staging systems do not consider separately
such neoplasms. Notably, the prognostic role of ENE has been
shown in diverse other cancer types [4, 5] and its importance
independently from speciﬁc anatomic subdistinctions is
further suggested by the case of carcinoma of pancreas versus
that of papilla of Vater [5].
In our meta-analysis and in our letter, we address the prog-
nostic impact of ENE in both colon and rectal cancers, but
without suggesting a unique staging system for these two neo-
plasms. Indeed, we recognize that the current TNM staging
system needs improvements, and the inclusion of ENE might be
one of these.
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Positron emission tomography
(PET) as a predictive measure
in patients with metastatic
pancreatic cancer and normal
CA19-9 levels at baseline
Two recent MPACT subanalyses (Chiorean et al. and
Ramanathan et al. Ann Oncol. 2016) demonstrated evidence that
decreases from baseline in carbohydrate antigen 19-9 (CA19-9)
and tumor uptake of radioactively labeled glucose (18F-FDG) as
measured by positron emission tomography (PET) imaging were
each signiﬁcantly associated with longer overall survival (OS) in
patients who received ﬁrst-line treatment with nab-paclitaxel plus
gemcitabine or gemcitabine for metastatic pancreatic cancer [1, 2].
These modalities are complementary approaches to monitor treat-
ment efﬁcacy in most patients. However, we raised the question of
whether tumor response measured by PET could predict outcome
for a subset of patients (15%–20%) with pancreatic cancer who do
not secrete elevated levels of CA19-9 [3, 4]. In the MPACT trial,
more patients experienced a metabolic response (MR) measured
by PET imaging than a tumor response measured by computed
tomography. PET imaging may be particularly valuable to predict
outcomes in patients without elevated baseline CA19-9 levels.
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